Addressing Barriers to Anti-hypertensive Medication Adherence Among PLWH Who Have Achieved Viral Suppression

Starting soon · Not applicable

Conditions studied: Hypertension, HIV-1-infection

In brief

Among those with hypertension, persons living with HIV (PWH) have a 50% higher risk of incident myocardial infarction compared to the general population, and they often fail to meet evidence-based treatment goals for hypertension. An important contributing factor for insufficient blood pressure control is non-adherence to antihypertensive medications. Research on medication adherence for PWH has largely focused on antiretroviral therapy adherence with limited focus on adherence to other non-AIDS condition medications. With a large proportion of PWH in the U.S. achieving viral suppression, providers may now have an opportunity to focus on the management of non-AIDS conditions like hypertension. However, because PWH who have achieved suppression have reduced clinic encounters (once or twice a year) there is potential loss of opportunity to effectively monitor and intensify hypertension treatment as needed an important opportunity to focus on preventing cardiovascular disease. CVD and other non-AIDS comorbidities. The study's overarching goal is to improve the hypertension outcomes for PWH on suppressive ART to reduce cardiovascular disease risk. In this study, we will identify and evaluate healthcare and patient-level factors that must be addressed in an intervention to increase hypertension medication adherence for PWH who have achieved viral suppression. We will use these factors to tailor an intervention and assess the feasibility and acceptability at the Duke ID clinic.

Key facts

Study ID

NCT05459077

Run by

Duke University

People needed

60

Starts

2026-09-03

Expected to finish

2026-09-30

Last updated by the study team

2026-07-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Aims 1A and 1B
• Age ≥18 years
• Confirmed HIV+ diagnosis
• Undetectable HIV viral load: defined as the most recent HIV viral load <200 copies/mL checked within the past year (assessed via chart abstraction)
• Hypertension diagnosis in medical records
• Taking an antihypertensive medication
• Receiving care at the Duke HIV clinic
• Aim 2
• HIV providers including infectious disease physicians, internists or advance practice practitioners who have a patient pool of PLWH under their care in the last 6 months.
• Aim 3A
• Stakeholders composed of willing participants recruited from the Duke ID clinic and may include, HIV providers, clinic directors, nurses, pharmacists, social workers, people living with HIV who have hypertension and take antihypertensive medications, and representatives of the community advisory boards, and any other key stakeholders.
• Aim 3 B
• Age ≥18 years
• Confirmed HIV+ diagnosis
• Receiving care at the Duke ID clinic
• Achievement of HIV suppression defined as having HIV-1 RNA <200 copies/ml
• Take antihypertensive medications
• Uncontrolled BP over a 12 months period defined by participants with systolic BP>130mmHg on ≥ 2 occasions in the past 12 months as indicated in the individual patient's electronic medical records

You may not qualify if…

• Aims 1A, 1B and 3B
• Severely hearing or speech impaired, or other disability that would limit participation in the intervention components
• In a nursing home and/or receiving in-patient psychiatric care
• Terminal illness with life expectancy < 4 months
• No reliable access to a telephone
• Pregnant, breast-feeding, or planning a pregnancy during the study period
• Planning to move out of the area in the next 6 months
• Non-English speaking.

Where it is running

• Duke University — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.